February 21, 2018 08:56 AM EST
R&D
Pharma

On a jour­ney to find and fu­el new biotech ven­tures, Ar­ix adds France's Ipsen to its net­work of part­ners

Amber Tong

Ar­ix Bio­science is clear­ly in a deal-mak­ing mood, strik­ing a new col­lab­o­ra­tion with France’s Ipsen (Eu­ronext: $IPN) just a day af­ter an­nounc­ing a part­ner­ship with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times